ALTERED SEROTONIN SIGNAL TRANSDUCTION IN DYSKINESIAS
运动障碍中血清素信号转导的改变
基本信息
- 批准号:2501490
- 负责人:
- 金额:$ 15.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-03-01 至 2001-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The long term objective of this research is to determine the
neurochemical mechanisms underlying antipsychotic-induced dyskinesias.
Antipsychotics, such as haloperidol, are widely used in the treatment
of schizophrenia and in agitated elderly patients. However, a
substantial proportion of patients receiving antipsychotic medication
experience motor disorders, often referred to as extrapyramidal side
effects (EPS). In fact, the incidence of EPS can approach 100 percent
in the elderly. Currently, no antipsychotics exist which are both safe
to use and free of EPS liability. It is hoped that by understanding
how these drugs affect neuronal systems involved in motor control,
safer compounds with no motoric side effects can be developed. One
neurotransmitter involved in motor control and implicated in mediating
EPS, is serotonin (5-hydroxytryptamine; 5-HT). Drugs which increase
central serotonergic activity can elicit orofacial dyskinesias in both
non-human primates and rats which have received antipsychotic
treatment, but not in vehicle-pretreated animals. Similar orofacial
dyskinesias are often seen in patients on antipsychotic medication.
While experimental data suggests that the serotonin 5-HT2c receptor
mediates orofacial dyskinesias, the effects of antipsychotics on 5-HT2c
mediated motor control and 5-HT2c-linked signal transduction in the
brain have not been studied. In this proposal it is hypothesized that
5-HT2c receptor supersensitivity in the basal ganglia contributes to
the EPS caused by antipsychotic drugs. The first specific aim is to
determine that 21 day administration of haloperidol to rats increases
5-HT2c mediated motor activity in vivo. This will be accomplished by
comparing 5-HT2c-mediated orofacial dyskinesias between haloperidol-
treated and vehicle-treated rats. The effects of haloperidol on 5-HT2c
receptor-mediated signal transduction in basal ganglia will also be
assessed in Aim I. For this purpose, 5-HT2c-stimulated phospholipase
C activity in caudate and substantia nigra of haloperidol-treated and
vehicle treated rats will be assayed. To determine the receptor
transduction mechanism through which supersensitivity occurs,
radioligand binding assays will assess changes in the 5-HT2c ligand
recognition site and immunoblotting techniques will assess changes in
guanine-nucleotide binding regulatory proteins which couple the 5-HT2c
site to phospholipase C. The second specific aim is to attenuate the
induction of dyskinesias and receptor supersensitivity by chronically
co-administering agents known to down-regulate the 5-HT2c receptor.
The success of this approach will be determined biochemically and
behaviorally as Aim I.
这项研究的长期目标是确定
抗精神病药引起的运动障碍的神经化学机制。
抗精神病药,例如氟哌啶醇,被广泛用于治疗
精神分裂症和躁动的老年患者。 但是,
接受抗精神病药物的患者中很大一部分
体验运动障碍,通常称为锥体外侧
效果(EPS)。 实际上,每股收益的发生率可以接近100%
在老人。目前,不存在任何抗精神病药
使用并不受EPS责任。 希望通过理解
这些药物如何影响与运动控制有关的神经元系统,
可以开发出没有摩尔副作用的更安全的化合物。一
与运动控制有关的神经递质与介导有关
EPS是5-羟色胺(5-羟色胺; 5-HT)。 增加的药物
中央血清素能活性都可以引起两者的口面性运动障碍
接受抗精神病药的非人类灵长类动物和大鼠
治疗,但不在媒介物预处理的动物中。 类似的口面
抗精神病药物患者经常会看到运动障碍。
虽然实验数据表明5-羟色胺5-HT2C受体
介导口质运动障碍,抗精神病药对5-HT2C的影响
介导的运动控制和5-HT2C连接的信号转导
尚未研究大脑。 在此提案中,假设
基底神经节中的5-HT2C受体超敏反应有助于
由抗精神病药引起的EPS。 第一个具体目的是
确定21天给大鼠氟哌啶醇的给药增加
5-HT2C体内介导的运动活性。 这将通过
比较氟哌啶醇之间的5-HT2C介导的口面性运动障碍
经过治疗和车辆处理的大鼠。 氟哌啶醇对5-HT2C的影响
受体介导的基础神经节中的信号转导也将是
在AIM I中进行评估。为此,5-HT2C刺激的磷脂酶
C活性在氟哌啶醇治疗的尾状和黑质中
将分析经车辆治疗的大鼠。 确定受体
超敏反应的转导机制,
放射性结合测定将评估5-HT2C配体的变化
识别地点和免疫印迹技术将评估变化
鸟嘌呤核苷酸结合调节蛋白,将5-HT2C融合
磷脂酶C.
长期诱导运动障碍和受体超敏反应
已知可下调5-HT2C受体的共同给药剂。
这种方法的成功将以生化确定,并
作为目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM A. WOLF其他文献
WILLIAM A. WOLF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM A. WOLF', 18)}}的其他基金
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
9039977 - 财政年份:2015
- 资助金额:
$ 15.76万 - 项目类别:
Serotonin Therapy for Parkinson's Disease and Neurodegenerative Disorders
血清素疗法治疗帕金森病和神经退行性疾病
- 批准号:
7931072 - 财政年份:2010
- 资助金额:
$ 15.76万 - 项目类别:
Serotonin Therapy for Parkinson's Disease and Neurodegenerative Disorders
血清素疗法治疗帕金森病和神经退行性疾病
- 批准号:
8391545 - 财政年份:2010
- 资助金额:
$ 15.76万 - 项目类别:
Serotonin Therapy for Parkinson's Disease and Neurodegenerative Disorders
血清素疗法治疗帕金森病和神经退行性疾病
- 批准号:
8597339 - 财政年份:2010
- 资助金额:
$ 15.76万 - 项目类别:
Serotonin Therapy for Parkinson's Disease and Neurodegenerative Disorders
血清素疗法治疗帕金森病和神经退行性疾病
- 批准号:
8196325 - 财政年份:2010
- 资助金额:
$ 15.76万 - 项目类别:
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
7272887 - 财政年份:2003
- 资助金额:
$ 15.76万 - 项目类别:
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
6945115 - 财政年份:2003
- 资助金额:
$ 15.76万 - 项目类别:
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
6804473 - 财政年份:2003
- 资助金额:
$ 15.76万 - 项目类别:
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
7099654 - 财政年份:2003
- 资助金额:
$ 15.76万 - 项目类别:
Drug-Enhanced Rehabilitation in Recovery from Stroke
中风恢复中的药物强化康复
- 批准号:
6677165 - 财政年份:2003
- 资助金额:
$ 15.76万 - 项目类别:
相似海外基金
The striatal cholinergic interneurons in Parkinson's disease and treatment
纹状体胆碱能中间神经元在帕金森病及其治疗中的作用
- 批准号:
9333674 - 财政年份:2017
- 资助金额:
$ 15.76万 - 项目类别:
The striatal cholinergic interneurons in Parkinson's disease and treatment
纹状体胆碱能中间神经元在帕金森病及其治疗中的作用
- 批准号:
9894969 - 财政年份:2017
- 资助金额:
$ 15.76万 - 项目类别:
The role of striatal cholinergic interneurons in Parkinson’s disease
纹状体胆碱能中间神经元在帕金森病中的作用
- 批准号:
9147020 - 财政年份:2015
- 资助金额:
$ 15.76万 - 项目类别:
MODULATION OF D2-LIKE DOPAMINE RECEPTOR-MEDIATED STRIATAL SIGNALING PATHWAYS BY
D2 样多巴胺受体介导的纹状体信号通路的调节
- 批准号:
7960145 - 财政年份:2009
- 资助金额:
$ 15.76万 - 项目类别:
ALTERED SEROTONIN SIGNAL TRANSDUCTION IN DYSKINESIAS
运动障碍中血清素信号转导的改变
- 批准号:
6165520 - 财政年份:1998
- 资助金额:
$ 15.76万 - 项目类别: